Circio Holding ASA · OSL:CRNA
Circio Holding ASA — Targovax — Investor Day (February 2021)
12 slides from Circio Holding ASA's investor day presentation, Feb 18, 2021
Slide 1: Capital Markets Day Agenda & speakers
PLEASE JOIN US FOR OUR CAPITAL MARKETS DAY Agenda & speakers With strong clinical data generated on ONCOS-102, 2:30-2:40 PM Welcome Øystein Soug, CEO, Targovax is moving into late-stage clinical development. Targovax In addition, a broad pipeline of preclinical assets creates a broad horizon of oppo
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of
Slide 3: Welcome
Welcome 2. Anti-PD1 refractory melanoma 3. ONCOS-102 development program 4. Immune activation 5. Preclinical pipeline update 6. 4Q update 7. Closing remarks
Slide 4: The Immuno-Oncology Revolution
THE IMMUNO-ONCOLOGY REVOLUTION > 500,000 patients treated per year > 3,000 ongoing clinical trials > 40% of US cancer patients eligible > 10 approved products 4 SOURCE: Research&Markets; Haslam & Prasad 2019, JAMA; Vaddepally et al. 2020, Cancers
Slide 5: First Generation Immuno-Oncology: Checkpoint Inhibitors
FIRST GENERATION IMMUNO-ONCOLOGY: CHECKPOINT INHIBITORS Cornerstone of current cancer treatment Deep and durable responses $25b annual sales globally 7 products approved to date, many more in development 5 SOURCE: GlobalData, Research&Markets
Slide 6: The Challenge: Make PD1 Checkpoint Inhibitors Work for More Patients
THE CHALLENGE: MAKE PD1 CHECKPOINT INHIBITORS WORK FOR 0-40% of treated patients respond MORE PATIENTS of responding >50% patients relapse 1 PD-1 checkpoint inhibitor monotherapy not sufficient 6 6 SOURCE: Haslam & Prasad, 2019, JAMA
Slide 7: The Solution: ONCOS-102 Immune Activation
THE SOLUTION: ONCOS-102 IMMUNE ACTIVATION Activates the body´s own T-cells against the cancer Unblinds the tumor to the immune system Reverses immunosuppressive defense mechanisms in the tumor 7
Slide 8: Targovax at a Glance
TARGOVAX AT A GLANCE Lead product candidate o Class-leading data in monotherapy and combinations with chemo and aPD-1 o Powerful immune activation ONCOS-102 o Ideal combination partner to aPD-1 Vision: o Path to market Unlock greater clinical benefits in cancer patients by deploying multifunctional
Slide 9: Clinical and Preclinical Pipeline
CLINICAL AND PRECLINICAL PIPELINE Product candidate Preclinical Phase 1 Phase 2 Collaborator Melanoma Combination w/Keytruda Colorectal cancer ONCOS-102 Combination w/Imfinzi Mesothelioma Combination w/pemetrexed/cisplatin ONCOS-200 series Next Gen viruses Novel mutRAS concepts 9 All rights to ONCOS
Slide 10: Early-Stage Development Successfully Completed – Entering Late-Stage Development
EARLY-STAGE DEVELOPMENT SUCCESSFULLY COMPLETED – ENTERING LATE-STAGE DEVELOPMENT Expansion opportunities Late-stage development Mesothelioma Colorectal cancer Early-stage development PD1 refractory melanoma Other indications Other IO combinations Clinical efficacy Platform development Immune activat
Slide 11: Product candidate pipeline: ONCOS-102
Product candidate Preclinical Phase 1 Phase 2 Collaborator ONCOS-102 Melanoma Combination w/Keytruda Colorectal cancer Combination w/Imfinzi Mesothelioma Combination w/pemetrexed/cisplatin ONCOS-200 series Next Gen viruses Novel mutRAS concepts 11
Slide 12: Dr. Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center
DR. ALEXANDER N. SHOUSHTARI, MEMORIAL SLOAN KETTERING CANCER CENTER Renowned expert in melanoma, with a research focus on checkpoint refractory melanomas Clinical Director and Assistant attending physician, Melanoma Services, Dept of Medicine, Memorial Sloan Kettering Cancer Center Principal investi